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Abstract
 
Mycobacterial lipids comprise a heterogeneous group of molecules capable of inducing T cell
responses in humans. To identify novel antigenic lipids and increase our understanding of lipid-
mediated immune responses, we established a panel of T cell clones with different lipid specificities.
Using this approach we characterized a novel lipid antigen belonging to the group of diacylated
sulfoglycolipids purified from 
 
Mycobacterium tuberculosis
 
. The structure of this sulfoglycolipid was
identified as 2-palmitoyl or 2-stearoyl-3-hydroxyphthioceranoyl-2
 
 
 
-sulfate-
 
 
 
-
 
  
 
-
 
d
 
-trehalose
(Ac
 
2
 
SGL). Its immunogenicity is dependent on the presence of the sulfate group and of the two
fatty acids. Ac
 
2
 
SGL is mainly presented by CD1b molecules after internalization in a cellular
compartment with low pH. Ac
 
2
 
SGL-specific T cells release interferon 
 
 
 
, efficiently recognize
 
M. tuberculosis
 
–infected cells, and kill intracellular bacteria. The presence of Ac
 
2
 
SGL-responsive
T cells in vivo is strictly dependent on previous contact with 
 
M. tuberculosis
 
, but independent
from the development of clinically overt disease. These properties identify Ac
 
2
 
SGL as a promising
candidate to be tested in novel vaccines against tuberculosis.
Key words: vaccination • intracellular bacteria • protection • cytotoxic CD8
 
  
 
T cells • lipids
 
Introduction
 
Tuberculosis remains a major health problem in the world,
despite significant progress in antibiotic therapy and health
care measures. It is unlikely that the global burden of tuber-
culosis will be eradicated without the use of effective vaccines,
which, however, are not available yet. The intracellular
location of 
 
Mycobacterium tuberculosis
 
, the causative agent of
tuberculosis, shields the bacilli from detection by antibod-
ies. Therefore, a protective response requires activation of
antigen-specific T cells, which may recognize different
types of ligands such as microbial peptides or lipids (1–3).
Conventional T cell responses directed against short pep-
tides presented by MHC molecules are implicated in protec-
tion during mycobacterial infection in several animal models
(4) and in human disease (5). Individuals with defective CD4
 
 
 
T cell responses and genetic deficiencies in mounting Th1-
dominated immune responses have an increased susceptibility
to 
 
M. tuberculosis
 
 infection (6). In addition, evidence for an im-
portant role of CD8
 
  
 
T lymphocytes is accumulating (7–12).
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1
 
H NMR, proton nuclear magnetic resonance;
Ac
 
2
 
SGL, 2-palmitoyl or 2-stearoyl-3-hydroxyphthioceranoyl-2
 
 
 
-sulfate-
 
 
 
-
 
  
 
-
 
d
 
-trehalose; BCG, bacillus Calmette Guérin; MALDI-
 
Tof
 
-MS, matrix-
assisted laser desorption/ionization-time of flight-mass spectrometry; m/z,
mass/charge; NMR, nuclear magnetic resonance; PIM, phosphatidyl-
 
myo
 
-
inositol mannosides; PPD, purified protein derivative of 
 
M. tuberculosis
 
;
SGL, sulfoglycolipids. 
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Another population of T cells, capable of recognizing
microbial lipids or self-glycosphingolipids, has been identi-
fied (13, 14). These antigens are amphipatic molecules
comprised of a hydrophilic cap bound to aliphatic hydro-
carbon chains. Specific T cells recognize complexes formed
by individual glycolipids associated with dedicated antigen-
presenting molecules belonging to the CD1 family. CD1
molecules resemble MHC class I antigen-presenting mole-
cules as they associate with 
 
 
 
2-microglobulin and assume
an MHC class I–like tertiary conformation. They have
evolved unique features enabling binding of glycolipids. In
the CD1–glycolipid complex the alkyl chains of glycolipids
are embedded inside deep hydrophobic pockets, whereas
the hydrophilic part of glycolipids is flanked by the two 
 
 
 
helices of CD1, which delimit the CD1 antigen-binding
groove. The TCR likely interacts with individual polar
residues contributed by the glycolipid and with amino acids
provided by the two 
 
  
 
helices of CD1 (15, 16).
Only few bacterial CD1 ligands have been identified to
date. Most notably, all of them were derived from myco-
bacterial species, possibly reflecting a special role for CD1-
restricted T cells in protection against tuberculosis. Specifi-
cally, free mycolic acids (13), glucose monomycolate (17),
mannophosphoisoprenoids (18), and lipoglycans such as
mannosylated lipoarabinomannan (19), lipomannan (19),
and phosphatidyl-
 
myo
 
-inositol mannosides (PIM; 20) are
capable of eliciting CD1-mediated T cell responses. With
the exception of mannophosphoisoprenoids, which stimu-
late CD1c-restricted T cells, all known antigens are pre-
sented by the CD1b molecule. This apparent bias to CD1b
restriction might derive from the unique capacity of CD1b
to recycle in the late endosomal or lysosomal compart-
ments (21, 22) and from the organization of its antigen-
binding pockets (23).
Mouse CD1d (24) and human CD1a (25) have gly-
colipid-binding capacities different from CD1b and it has
been proposed that each CD1 molecule has evolved the ca-
pacity to present unique types of lipid antigens (18). The
structures of human CD1c and CD1d are not available yet
and, therefore, it is difficult to predict the presence of biased
binding modes. However, all CD1 molecules can bind and
present to T cells the same glycolipids with short acyl chains
(26), thus pointing to overlapping presentation capacities.
To understand the role of lipid-specific T cells in protec-
tion against tuberculosis it is important to clarify whether
the repertoire of immunogenic lipids synthesized by 
 
M. tu-
berculosis
 
 is limited to a few molecules or rather comprises a
wide spectrum of structurally distinct molecules. Identifica-
tion of the most immunogenic lipids would facilitate selec-
tion of candidate molecules for a lipid-based vaccine against
tuberculosis.
A significant issue concerns the relative contribution of
lipid-specific CD4
 
  
 
and CD8
 
  
 
T cell subsets to the control
of mycobacterial infection. In tuberculosis patients the ma-
jority of lipid-specific T cells circulating in the peripheral
blood appear to be CD4
 
  
 
(27). Notably, recent findings in-
dicate that most of CD8
 
  
 
T cells activated by bacillus Cal-
mette Guérin (BCG)-infected APCs recognize mycobacte-
rial lipid antigens, whose nature remains unknown (28). As
CD8
 
  
 
T cells participate in protective responses (9, 29), it
is important to identify the nature of lipid antigens activat-
ing this T cell subset.
Here we identify and structurally characterize a novel
mycobacterial ligand, expressed by virulent bacilli, which
activates CD8
 
 
 
, CD1b-restricted T cells. T cells specific
for this new antigen show a strong bactericidal capacity and
are present in the large majority of tuberculosis patients and
purified protein derivative of 
 
M. tuberculosis
 
 (PPD)
 
  
 
healthy
donors, but not in PPD
 
  
 
donors.
 
Materials and Methods
 
Bacterial Strain and Culture Conditions. M.  tuberculosis
 
 H37Rv
(American Type Culture Collection [ATCC] 27294) was grown
at 37
 
 
 
C on Sauton’s medium as surface biofilm. Cells were har-
vested after 4 wk, separated from the culture media, and left in
chloroform/methanol (2:1, vol/vol) for 2 d at room temperature
to kill bacteria.
 
Lipidic Fractions Used for Generation of T Cell Clones.
 
Bacterial
cells were suspended in chloroform/methanol (1:1, vol/vol) and
filtered four times. The chloroform/methanol extract was con-
centrated and partitioned between water and chloroform. The
chloroform phase was applied to an anion exchange Sep-pak
 
®
 
cartridge (Waters Accell™
 
 
 
Plus QMA; Waters Corporation)
eluted successively by 5 ml chloroform/methanol/water (60:35:8,
vol/vol/vol) to elute neutral compounds and then with 5 ml
chloroform/methanol/water (60:35:8, vol/vol/vol) containing
0.1 M ammonium acetate to elute negatively charged com-
pounds (as phospholipids). PIM
 
2
 
-enriched fraction was prepared
as previously described (30).
 
Purification of the Novel Lipidic M. tuberculosis Antigen.
 
Bacte-
rial cells were suspended in chloroform/methanol (1:1, vol/vol)
and filtered four times. The chloroform/methanol extract was
concentrated and constituted the whole lipid extract (22.7 g),
which was further partitioned between water and chloroform.
The chloroform phase was evaporated and constituted the lipidic
fraction (5.3 g), which was redissolved in a minimum volume of
chloroform. The addition of acetone overnight at 4
 
 
 
C led to for-
mation of a precipitate, which was centrifuged (3,000 
 
g
 
 at 4
 
 
 
C for
15 m) to generate an acetone-soluble phase (fraction 1; 2.8 g) and
an acetone-insoluble phase (fraction 2; 2.2 g). The “acetone-sol-
uble” phase (fraction 1; 1 g) was then fractionated on a silicic acid
column (19 
 
  
 
2 cm) irrigated by chloroform (fraction 4; 120 ml),
chloroform containing 10 (fraction 5 and 6; 100 ml), 20 (fraction
7; 100 ml), and 30% (fraction 8; 200 ml) methanol, and finally by
chloroform/methanol/water (6:4:0.4, vol/vol/vol; fraction 9;
100 ml). Fractions 5 and 6 were found to contain Ac
 
4 
 
sulfogly-
colipids (SGL) and Ac
 
3
 
SGL, respectively, and fraction 7 was
found to contain 2-stearoyl-3-hydroxyphthioceranoyl-2
 
 
 
-sulfate-
 
 
 
-
 
  
 
-
 
d
 
-trehalose (Ac
 
2
 
SGL).
Fraction 7 was further purified by reverse phase chromatogra-
phy. This purification was realized on a Sep-pak
 
® 
 
cartridge (Sep-
pak
 
® 
 
Light C18 cartridge; Waters Corporation) eluted two times
with 2 ml methanol/water (9:1, vol/vol; fractions 7.1 and 7.2),
two times with 2 ml methanol (fractions 7.3 and 7.4), and finally
with 5 ml chloroform (fraction 7.5).
Purifications were checked by TLC on aluminum-backed sil-
ica gel plates (Alugram Sil G; Macherey-Nagel) using as migra- 
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tion solvent chloroform/methanol (9:1, vol/vol). Orcinol (3,5-
dihydroxytoluene [Sigma-Aldrich] at 0.3% dissolved in H
 
2
 
SO
 
4 
 
at
10%) and anthrone (9,10-dihydro-9-oxo-anthracene [Sigma-
Aldrich] at 0.2% dissolved in H
 
2
 
SO
 
4 
 
at 85%) were used to detect
carbohydrate-containing lipids.
 
Generation of Glycolipid-specific Bulk T Cell Lines and Clones.
 
All experiments were performed using RPMI 1640 medium con-
taining 2 mM glutamine, 1 mM Na pyruvate, 1% nonessential
amino acids (all from Cambrex), 100 
 
 
 
g/ml kanamycin (GIBCO
BRL), and 5% AB human serum (Swiss Red Cross). T cell lines spe-
cific for mycobacterial lipids were generated by stimulating PBMCs
(10
 
6
 
/well) from a PPD
 
  
 
healthy donor that had been in contact with
tuberculosis patients for several years and vaccinated with BCG 27 yr
before blood was drawn for these experiments. PBMCs were plated
in 24-well plates with autologous CD1
 
  
 
APCs (10
 
5
 
/well), generated
as previously described (14), and pulsed with different mycobacterial
fractions (see Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20031097/DC1). After 5 d of culture, 10 U/ml recombi-
nant human IL-2 was added in each well and cells were split using
the same medium according to their proliferation rate. T cell clones
were generated as previously described (31).
 
Analysis of CD1 Restriction.
 
CD1 restriction was investigated
by inhibiting T cell activation using the following anti-CD1
mAbs at 10 
 
 
 
g/ml 30 min before the addition of T cells: WM-25
(anti-CD1b; Immunokontakt), OKT6 (anti-CD1a), and L161
(anti-CD1c; Instrumentation Laboratory). W6-32 (anti–MHC
class I) and L243 (anti–MHC class II) were used as control anti-
bodies. In some experiments CD1b-transfected THP-1 cells (32)
were used as APCs.
 
Antigen Presentation Assays.
 
CD1
 
  
 
APCs, CD1b-transfected
THP-1 cells, HL-60, U-937, or MonoMac6 (ATCC) were pre-
incubated at 5 
 
  
 
10
 
4 
 
cells/well for 2 h at 37
 
 
 
C with 1–10 
 
 
 
g/ml
sonicated antigen before the addition of T cells (5 
 
  
 
10
 
4
 
/well in
triplicate). After 36 h, released TNF-
 
  
 
and IFN-
 
  
 
were measured
using sandwich ELISA kits (Instrumentation Laboratory). Data
are expressed as mean nanogram/milliliter or picogram/millili-
ter 
 
  
 
SD of triplicates. All experiments were repeated at least two
times. Sulfatide was purchased from Fluka.
In some experiments CD1
 
  
 
APCs were fixed as previously de-
scribed (32) and used as APCs. To investigate the requirements
for antigen internalization, 10
 
6 
 
CD1
 
  
 
APCs were preincubated
for 1 h at 4
 
 
 
C or at 37
 
 
 
C in the presence or absence of 80 
 
 
 
M
chloroquine or 20 
 
 
 
M monensin and then pulsed with 10 
 
 
 
g/ml
Ac
 
2
 
SGL for an additional 3 h. After washing, CD1
 
  
 
APCs were
fixed and used to stimulate T cells. The sulfatide-specific
DS1C9b T cell clone has been described (26).
 
Desulfatation of Ac
 
2
 
SGL.
 
1 mg Ac
 
2
 
SGL was dissolved in 1 ml
of a 50-mM solution of HCl in methanol and kept at room tem-
perature for 16 h. 3 ml chloroform, 0.5 ml methanol, and 1 ml of
0.2% sodium acetate were then added. The lower phase was
washed twice with 2 ml chloroform/methanol/water (3:48:47,
vol/vol/vol), dried, and tested on silica gel high performance thin
layer chromatography plates using chloroform/methanol (9:1) as
migration solvent to confirm loss of the sulfate group. The gly-
colipids were visualized by orcinol staining.
 
SGL Peracetylation.
 
150 
 
 
 
g SGL were dissolved in acetic an-
hydride/anhydrous pyridine (1:1, vol/vol) at 80
 
 
 
C for 2 h. The
reaction mixture was dried under stream of nitrogen. The reac-
tion was checked by 1D and 2D proton nuclear magnetic reso-
nance (
 
1
 
H NMR) and by matrix-assisted laser desorption/ioniza-
tion-time of flight-mass spectrometry (MALDI-
 
Tof
 
-MS).
 
MALDI-Tof-MS.
 
Analysis by MALDI-
 
Tof
 
-MS was per-
formed on a Voyager DE-STR (PerSeptive Biosystems) using the
reflectron mode. Ionization was effected by irradiation with
pulsed UV light (337 nm) from an N2 laser. SGL samples were
analyzed by the instrument operating at 20 kV in the negative ion
mode using an extraction delay time set at 200 ns. Typically,
spectra from 100 to 250 laser shots were summed to obtain the fi-
nal spectrum. All of the samples were prepared for MALDI anal-
ysis using the on-probe sample cleanup procedure with cation
exchange resin (33). The HABA matrix (2-[4-hydroxy-phenyl-
azo]-benzoic acid; Sigma-Aldrich) was used at a concentration of
 10 mg/ml in ethanol/water (1:1, vol/vol). Typically, 0.5  l
SGL sample (10  g) in a CHCl3-CH3OH solution and 0.5  l of
the matrix solution, containing  5–10 cation exchange beads,
were deposited on the target, mixed with a micropipette, and
dried under a gentle stream of warm air. The measurements were
externally calibrated at two points with mycobacterial PIM.
MALDI-Tof-MS/MS Analysis. Positive MALDI mass spectra
of Ac2SGL, using  -cyano-4-hydroxycinnamic acid (Sigma-
Aldrich) as matrix, were recorded using a QSTARPULSAR
mass spectrometer equipped with an oMALDI ionization source
(Applied Biosystems). Pseudomolecular ions were observed at
mass/charge (m/z) 1,323 and 1,295, which were used as precur-
sor ions for MS/MS studies.
Nuclear Magnetic Resonance (NMR) Analysis. NMR spectra
were recorded with an Avance DMX500 spectrometer (Bruker
GmbH) equipped with an Origin 200 SGI using Xwinnmr 2.6.
Native Ac2SGL and peracetylated Ac2SGL were dissolved in
CDCl3-CD3OD, (4:1, vol/vol) and CDCl3, respectively, and an-
alyzed in 200   5 mm 535-PP NMR tubes at 295 K. Proton
chemical shifts are expressed in parts per million downfield from
the signal of the chloroform ( H/TMS 7.27 and  C/TMS 77.7).
All the details concerning correlation spectroscopy and homonu-
clear Hartmann-Hahn spectroscopy sequences used and experi-
mental procedures were as previously described (30).
Activation of T Cells by Infected CD1  APCs. Monocytes were
purified from freshly isolated PBMCs by adherence on plastic for
1 h. Cells were treated with 1,000 U/ml GM-CSF (Novartis) and
1,000 U/ml IL-4 (PBH). After 3 d all cells expressed high levels of
CD1a, CD1b, and CD1c, and are referred to as CD1  APCs (13).
These cells were infected with M. tuberculosis H37Rv (from the
collection of the Microbiology Unit in Erlangen) at a multiplicity
of infection of 5 as previously described (34). Infected cells were
detached (with 1 mM EDTA; Sigma-Aldrich) and plated in a 96-
well plate at a density of 2   104 cells together with 105 T cells in
each well. Supernatants were collected after 48 h, filtered (0.2
 m), and tested for presence of IFN-  by sandwich ELISA (En-
dogen) with a sensitivity of 15 pg/ml.
Killing of Intracellular M. tuberculosis by T Cells. CD1  APCs
were infected with the virulent strain M. tuberculosis H37Rv at a
multiplicity of infection of 5. The efficiency of infection was
43   6% as determined by auramine rhodamine stain. T cells
were added at different effector target ratios as indicated. All con-
ditions were set up as duplicates. After 72 h cells were lysed with
0.3% saponin (Sigma-Aldrich) and sonicated in a water bath to
disperse bacterial aggregates. Lysates were then plated in 10-fold
dilutions on 7H11-agar plates (Becton Dickinson). After 21 d of
culture CFU were enumerated.
Recognition of Ac2SGL by Lymphocytes from Tuberculosis Patients.
PBMCs were purified from the blood of healthy donors and tu-
berculosis patients after informed consent was given. All suffered
from pulmonary tuberculosis (culture positive). 21 patients were
male, 10 female, and the age ranged from 30–62 (median 39).
Blood was drawn within the first 2 wk after initiation of antitu-
berculosis therapy. 22 patients were PPD  and in 9 patients test-New M. tuberculosis Glycolipid Antigens for Human T Cells 652
ing was not performed because the diagnosis of tuberculosis was
obvious. Healthy donors with an induration of 5 mm after stan-
dard tuberculin skin testing without any clinical signs of disease
were scored as PPD  healthy. PBMCs (105/well) were cultured
with autologous CD1  APC (2   104/well) in the presence or
absence of 10  g/ml Ac2SGL. After 24 h supernatants were col-
lected and tested for the presence of IFN-  by sandwich ELISA.
PBMCs were kept at 37 C in supplemented RPMI 1640 me-
dium (see above) during the 3 d of autologous monocytes differ-
entiation to DCs.
Online Supplemental Material. The purification scheme of
Ac2SGL is depicted in Fig. S1. The Ac2SGL-specific CD8  T cell
clones do not react against Ac3SGL and Ac4SGL, which are
present in fractions 6 and 5, respectively. This is illustrated in Fig.
S2. Restriction by CD1b was also confirmed by inhibiting the
response to CD1b-transfected THP-1 APCs using anti-CD1b
mAbs. WM-25 anti-CD1b antibodies were added at 10 g/ml 30
min before the addition of T cells (Fig. S3). The dose response
curve of synthetic SGL analogue is compared with that of the
natural Ac2SGL in Fig. S4.
In Table S1 the mass spectra peaks were assigned to the differ-
ent acyl forms of Ac2SGL, which differ by the hydrocarbon chain
lengths. In Table S2 the 1H chemical shifts of the native and per-
acetylated Ac2SGL are presented. Figs. S1–S4 and Tables S1
and S2 are available at http://www.jem.org/cgi/content/full/
jem.20031097/DC1.
Results
T Cell Clones as Tools to Identify Relevant M. tuberculosis
Lipid Antigens. To assess the immunogenicity of mycobac-
terial lipids we used the strategy of purifying lipid fractions of
M. tuberculosis H37Rv strain according to their polarity and
charge. Three fractions were used: one enriched in nega-
tively charged compounds, one essentially made of neutral
compounds, and a third fraction enriched in phosphatidyl-
myo-inositol dimannosides (PIM2). Bulk lines of T cells were
established using each of these preparations and showed spe-
cific responses against the same lipid fractions used for the
initial stimulation (unpublished data). These lines were de-
rived from PBMCs of one healthy donor highly reactive to
PPD. From these lines 10 individual T cell clones were es-
tablished by limiting dilution. All the clones were CD1 re-
stricted, expressed the TCR   , and belonged to two dis-
tinct subsets: eight were CD4 , whereas two were CD8 .
Because only few mycobacterial antigens stimulating CD8 
T cells are known (29), CD8  cells provide unique effector
functions in mycobacterial disease (35, 36), and most of
CD8  cells reacting to BCG-infected APCs are CD1 re-
stricted (28), we chose to focus on defining the antigen spec-
ificity of CD8  clones Z4B27 and Z4A26.
Purification and Chemical Characterization of a Novel M. tu-
berculosis Lipid Antigen. To identify the antigenic lipids, a
more sophisticated purification was used. First, a pool of lip-
ids was generated by extraction of mycobacterial H37Rv
cells with a mixture of chloroform/methanol (1:1, vol/vol).
Hydrophilic compounds were removed from this pool by
water/chloroform partition and the lipids were then al-
lowed to precipitate in acetone, a solvent known to precip-
itate phospholipids. An acetone-soluble phase and an ace-
tone-insoluble phase were obtained, indicated as fractions 1
and 2, respectively (Fig. S1). CD8     T cell clones reacted
to the acetone-soluble phase (unpublished data). To gain in-
sights into the molecules present, this latter fraction (fraction
1) was analyzed by MALDI-Tof-MS in negative mode.
The mass spectrum revealed peaks assigned to deproto-
nated molecular ions [M-H]  typical of phosphatidyl-myo-
inositol (m/z 851) and PIM (Ac3PIM2 at m/z 1,413 and
Ac3PIM6 at m/z 2,061; Fig. 1 A). Furthermore, three fami-
lies of SGL differing in their acylation degree and fatty acyl
appendage structure were also detected. SGL is used to de-
scribe the global family of sulfoglycolipids, composed of
 -  -d-trehalose-2 -sulfate core acylated by two to four fatty
acids (Fig. 1, inset). In AcxSGL, x refers to the total number
of acyl groups, whatever the nature of the fatty acids,
which could be either palmitic, stearic, hydroxyphthiocera-
noic, or phthioceranoic acids. SGL were initally described
as sulfolipids (37) acylated by three or four fatty acids. In
the high mass range, a set of peaks is dominated by the
deprotonated molecular ions [M-H]  at m/z 2,429 and
2,457, typifying Ac4SGL with three hydroxyphthiocera-
noic acid residues and either one palmitic or one stearic
acid residue. In the middle mass range, a set of peaks with
the major ion species at m/z 1,867 correspond to Ac3SGL
containing two hydroxyphthioceranoic acids and one
stearic or one palmitic acid residue. Finally, in the low mass
range, a third set of peaks was observed to be dominated by
Figure 1. Characterization of the T cell antigen. Negative MALDI-Tof
mass spectra of (A) the “acetone-soluble” fraction (fraction 1) and (B)
fraction 7 obtained after silicic acid column chromatography containing the
stimulatory activity. See Table S1 for peak interpretation. Inset: Structural
model of the M. tuberculosis SGL with R corresponding to hydroxy-
phthioceranoic, palmitic, or stearic acid. Ac4SGL contains three hydroxy-
phthioceranoic acids and one palmitic or stearic acid, Ac3SGL contains
two hydroxyphthioceranoic acids and one palmitic or stearic acid, and
Ac2SGL contains one hydroxyphthioceranoic acid and one palmitic or
stearic acid. MS peaks are labeled with mass values calculated using C  
12, H   1, O   16, P   31, and S   32.Gilleron et al. 653
the deprotonated molecular ions at m/z 1,249 and 1,277
typifying Ac2SGL with one hydroxyphthioceranoic acid
and either one palmitic or stearic acid residue, respectively.
The acetone-soluble phase was further fractionated on si-
licic acid column irrigated by chloroform containing in-
creasing amounts of methanol (Fig. S1). CD8  T cell clones
were stimulated by fraction 7 and eluted with a mixture of
chloroform containing 20% of methanol. The different frac-
tions were analyzed by negative MALDI-Tof-MS. Mass
spectrum of the stimulatory fraction 7 (Fig. 1 B) is complex
and dominated by peaks at m/z 1,249 and 1,277 assigned to
Ac2SGL. The acyl appendages were unambiguously as-
signed to hydroxyphthioceranoic and palmitic or stearic ac-
ids by gas chromatography, gas chromatography-mass spec-
trometry, and electronic impact-mass spectrometry analysis
(unpublished data). The acyl appendages of Ac2SGL (mol
wt 1,250) correspond to palmitic acid and hydroxyphthio-
ceranoic acid with m   14 and n   7, whereas Ac2SGL of
mol wt 1,278 contains stearic acid and hydroxyphthiocera-
noic acid with m   14 and n   7 or palmitic acid residue
and hydroxyphthioceranoic acid with m   16 and n   7
(see Table S1 for their assignment, available at http://
www.jem.org/cgi/content/full/jem.20031097/DC1). Be-
sides these two major Ac2SGL acyl forms, the mass spec-
trum shows other peaks distant of 14 mass units, assigned to
Ac2SGL acyl forms differing by the chain length of the hy-
droxyphthioceranoic acid (Table S1). In summary, all the
peaks of the MALDI-Tof mass spectrum of fraction 7 were
assigned to Ac2SGL acyl forms. The two fractions eluted
with 10% of methanol (fractions 5 and 6) were found by
MALDI-Tof-MS to contain Ac3SGL and Ac4SGL, respec-
tively (unpublished data). These fractions did not stimulate
Z4B27 and Z4A26 T cell clones (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20031097/DC1).
Fraction 7 was further purified by reverse phase chroma-
tography and five new subfractions (7.1–7.5) were obtained.
Their purity was controlled by silicic acid TLC (Fig. 2 A)
and negative MALDI-Tof-MS (Fig. 2 B). Fraction 7.1 is a
mixture of several compounds, none of them corresponding
to Ac2SGL. In contrast, TLC shows one spot for fraction 7.3
and 7.4 and two spots for fraction 7.5. MALDI-Tof mass
spectra of the three fractions highlighted the presence of
Ac2SGL typified by the previously assigned [M-H]  ions at
m/z 1,249 and 1,277. As expected, this reverse phase chro-
matography allowed the separation of the Ac2SGL acyl forms
according to the chain length of their hydroxyphthiocera-
Figure 2. Identification of the
active ligand present in fraction 7
as Ac2SGL. (A) TLC analysis of
the components present in fraction
7 after reverse chromatography
purification revealed by orcinol.
Numbers indicate the subfractions
tested in the following panels.
(B) Negative MALDI-Tof mass
spectra of the subfractions 7.1,
7.3, 7.4, and 7.5. See Table S1
for peak interpretation. (C) Stimu-
lation of the Z4B27 T cell clone
by ( ) subfraction 7.1 from A,
( ) subfraction 7.3, ( ) subfrac-
tion 7.4, ( ) subfraction 7.5, ( )
desulfatated Ac2SGL, and ( )
control active fraction 7 as mea-
sured by IFN-  ELISA. Bars in-
dicate SD.New M. tuberculosis Glycolipid Antigens for Human T Cells 654
noic acid. Indeed, fraction 7.3 is characterized by Ac2SGL
containing hydroxyphthioceranoic acid with shorter chains
(m/z 1,039, 1,067, 1,123, 1,151, 1,165, 1,193, and 1,249)
than those of Ac2SGL fractions 7.4 (m/z 1,249, 1,277, and
1,291) and 7.5 (m/z 1,277, 1,305, 1,319, 1,333, and 1,361).
In summary, the sub-fractions 7.3, 7.4, and 7.5 are com-
posed of Ac2SGL acyl forms that differ by the hydrophthio-
ceranoic acid chain length (Table S1).
The capacity of the different subfractions to stimulate the
CD8  T cell clones was investigated by measuring INF- 
production. As shown in Fig. 2 C, the activity was re-
stricted to the fractions 7.3, 7.4, and 7.5. Taken together,
these data demonstrated that Ac2SGL acyl forms are the
immunogenic compounds of the CD8  T cell clones.
To support the antigen structure and the contribution of
the sulfate group to immunogenicity, the sulfate group was
removed under mild acidic conditions. Desulfatation of
Ac2SGL completely abrogated IFN-  production (Fig. 2
C), supporting the previous assignment of the antigenic ac-
tivity to Ac2SGL, but also revealing that immunogenic ac-
tivity of Ac2SGL requires the sulfate residue.
The immunological importance of the sulfate group
prompted mass spectrometry and NMR studies aimed to
precisely assign the position of sulfate as well as the acyl ap-
pendages. We performed a MALDI-MS analysis of Ac2SGL
in positive mode using a QSTARPULSAR mass spectrom-
eter (unpublished data). The mass spectrum was dominated
by two peaks at m/z 1,295 and 1,323, which were assigned
to cationized molecular ions of the sodiated Ac2SGL (M-
H 2Na) . MS/MS spectra of the precursor ions 1,295 and
1,323 showed loss of HOSO3
  Na  for both compounds, in
agreement with the presence of a sulfate group. Further-
more, loss of sulfoanhydroGlc and sulfoGlc was detected
from both precursor ions, revealing that the two fatty acyl
appendages including hydroxyphthioceranoic and palmitic
or stearic acids were located on the Glcp moiety, which did
not bear the sulfate group (Glcp-I; unpublished data).
This result was in agreement with 1D and 2D 1H NMR
experiments. In the anomeric zone of the 1D 1H spectrum
(Fig. 3), four signals were observed, namely I1, II1, II2, and
II3. The resonances I1 and II1 were assigned to the two ano-
meric protons of the  -  -trehalose core. Starting from
these protons, the complete spin systems of both Glcp units
could be determined from 1H-1H correlation spectroscopy
and homonuclear Hartmann-Hahn spectroscopy experiments
(Table S2, available at http://www.jem.org/cgi/content/
full/jem.20031097/DC1). These data allowed assignment
of the resonances II2 and II3 to H2 and H3 of the Glcp-II,
respectively. The downfield shifts of the H2 and H3 protons
proved that the fatty acyl appendages (hydroxyphthiocera-
noic acid and palmitic or stearic acids) were located on C2
and C3 of Glcp-II. In addition, from the comparative analy-
sis of the proton chemical shifts (Table S2,  ) of the native
and peracetylated SGL, the sulfate residue was located on
the C2 of the Glcp-I. Indeed, variations in chemical shifts of
 1 ppm for H3 and H4 indicated that these positions were
not substituted in the native molecule. A very weak chemi-
cal shift variation was observed for H2 and H3 of Glp-II
(0.27 and 0.45 ppm, respectively) in agreement with the fact
that fatty acyl appendages were located on C2 and C3. A
high chemical shift variation was observed for H3 and H4 of
Glp-I (1.54 and 1.71 ppm, respectively) and H4 of Glp-II
(2.03 ppm) in agreement with the fact that these positions
were not substituted in the native molecule. The sulfate was
located on the C2 of Glp-I as a small variation (0.44 ppm)
was observed (Fig. 3, inset). Moreover, the exactness of the
proposed structure was definitely proven by comparison of
proton chemical shifts of natural Ac2SGL with a synthetic
molecule, i.e., 2,3-dipalmitoyl-2 -sulfate- -  -d-trehalose
(not depicted; the synthesis of this molecule will be reported
elsewhere).
To confirm that Ac2SGL is the recognized antigen, this
synthetic molecule was also used to stimulate T cells. A sig-
nificant stimulation of Ac2SGL-specific T cells was ob-
served (Fig. 4 A), which did not occur when sulfatide-spe-
cific T cells were used (Fig. 4 B). The synthetic molecule
stimulated the specific T cells with a lower efficacy than the
natural Ac2SGL, likely due to the lack of the hydroxy-
phthioceranoic acyl chain.
In conclusion, 2-palmitoyl or 2-stearoyl-3-hydroxy-
phthioceranoyl-2 -sulfate- -  -d-trehalose (Ac2SGL) is the
antigen recognized by CD8  T cell clones (Fig. 4 C).
Requirements for Presentation of Ac2SGL to T Cells. To
determine the restricting element of Ac2SGL we used APCs
from different sources to stimulate CD8  cells. Autologous
CD1  APCs but not PBMCs nor EBV-transformed lym-
phoblastoid cell lines presented Ac2SGL to specific T cells
(Fig. 5 A). Heterologous CD1  APCs from multiple donors
were almost equally efficient in presenting this ligand, sug-
gesting that the response was restricted by a nonpolymor-
Figure 3. Structure determination of Ac2SGL by 1D 1H NMR spectrum
analysis (  1H: 0–7.8). The structure of Ac2SGL is shown in the inset. The
two glucose units are labeled I and II, as indicated in the inset. R corre-
sponds to hydroxyphthioceranoic, palmitic, or stearic acid.Gilleron et al. 655
phic molecule (Fig. 5 B). Furthermore, the promyelocytic
HL-60, the histiocytic U-937, and the macrophage Mono-
Mac6 cell lines did not present Ac2SGL. These findings ex-
clude that presentation of this antigen is a property of all
cells belonging to the monocytic lineage and suggest that a
nonubiquitous presenting molecule is involved. Because
CD1 molecules are nonpolymorphic and nonubiquitous
we explored the possibility that Ac2SGL was presented by
these molecules. Ac2SGL is presented by CD1b as shown
by inhibition of T cell activation by anti-CD1 mAbs (Fig.
5 C) and efficient presentation by CD1b-transfected but
not mock-transfected THP-1 cells (Fig. 5 D).
An important question is in which cellular compart-
ment is the Ac2SGL ligand loaded on CD1b? The current
consensus is that lipids with long acyl chains are loaded in
late endosomal compartments in which low pH and par-
tial unfolding of CD1b molecules facilitate insertion of
long fatty acids in the CD1 lipid-binding pockets (20). As
Ac2SGL contains the C32 long hydroxyphthioceranoic
acid, we investigated whether intracellular internalization
in APCs is necessary for presentation. Pulsing of THP-1
CD1b cells with Ac2SGL at 4 C or in the presence of
monensin, two conditions that prevent internalization of
surface-bound molecules, prevented T cell activation (Fig.
6 A), suggesting that internalization is required. This was
confirmed by lack of presentation when CD1  APCs
were first fixed and then pulsed with the antigen (Fig. 6
C). On the contrary, the same APCs were fully capable of
activating specific T cells when they were first pulsed and
then fixed. To further test the requirements for internal-
ization, CD1  APCs were pulsed in the presence of chlo-
roquine, an agent that blocks endosomal acidification. In
addition, this treatment prevented T cell activation (Fig. 6
A), further suggesting that presentation occurs only when
CD1b and Ac2SGL converge in an endosomal compart-
ment undergoing acidification.
All of these treatments did not abolish presentation of an-
other glycolipid, sulfatide, to specific T cells, thus excluding
possible artifacts due to APC treatment (Fig. 6, B and D).
Figure 4. Biological activity of a synthetic analogue and structure of
the natural active molecule. (A) Activation of the Ac2SGL-specific T cell
clone Z4B27 using synthetic 2,3-dipalmitoyl- - ’-d-trehalose-2 -sulfate
(SGL analogue). Purified Ac2SGL and synthetic Ac2SGL analogue were
used at 10  g/ml. Release of IFN-  was tested by ELISA. The results are
representative of two experiments. Bars indicate SD. (B) Control with
sulfatide-specific DS1C9b T cell clone. Sulfatide was used at 10  g/ml.
Bars indicate SD. (C) Structure of M. tuberculosis Ac2SGL. The presented
structure corresponds to one of the major Ac2SGL acyl forms (mol wt 1,250).
Figure 5. CD1b-restricted presentation of Ac2SGL. (A) Autologous
CD1  APCs and not PBMCs or EBV-transformed lymphoblastoid cell
lines present Ac2SGL. (B) Presentation by CD1  APCs isolated from
different individuals and by cell lines of the monocytic lineage. (C) Inhi-
bition of T cell activation by anti-CD1b mAbs. (D) Presentation by
CD1b-transfected THP-1 cells. Release of IFN-  by the Z4B27 T cell
clone was measured by ELISA. White bars represent response in the absence
of antigen. A second Ac2SGL-specific and CD1b-restricted T cell clone
gave similar results (unpublished data). Bars indicate SD.
Figure 6. Requirements for presentation of Ac2SGL. (A) Presentation
of Ac2SGL is inhibited when APCs are pulsed with Ac2SGL (solid bars) at
4 C, or in the presence of monensin or chloroquine. White bars represent
response in the absence of antigen. (C) APCs pulsed and then fixed
present Ac2SGL. (B and D) The same treatments did not affect presentation
of sulfatide to the CD1b-restricted and sulfatide-specific DS1C9b T cell
clone. (A and C) Release of IFN-  by the Z4B27 T cell clone measured
by ELISA. Similar results were obtained in three additional experiments
and also with the Z4A26 T cell clone (unpublished data). Medium indicates
response in the absence of treatment. Bars indicate SD.New M. tuberculosis Glycolipid Antigens for Human T Cells 656
Immunogenicity of Ac2SGL. Important requirements for
a promising vaccine compound are the capacity to prime T
cells that recognize M. tuberculosis–infected cells and kill the
intracellular pathogen. To address these key issues we incu-
bated CD8  T cells with CD1  APCs that had been in-
fected with virulent M. tuberculosis H37Rv (Fig. 7, A and B)
and measured antigen-specific release of IFN- . Only in-
fected but not uninfected CD1  APCs stimulated Ac2SGL-
specific cytokine release by T cells. Furthermore, IFN- 
was released only when T cells were present, suggesting that
this cell population and not DCs is responsible for IFN- 
production. The amount of the cytokine measured was
comparable when M. tuberculosis–infected or Ac2SGL-pulsed
CD1  APCs were used, demonstrating that the presentation
of this antigen during infection is highly efficient.
Because killing of intracellular pathogens is a key func-
tion of CD8  T cells, we investigated the antimicrobial ac-
tivity of Ac2SGL-specific T cells. M. tuberculosis–infected
cells were incubated with increasing numbers of Ac2SGL-
specific T cells and the number of surviving bacteria was
determined after 72 h. The number of bacteria significantly
decreased and correlated with the number of effector cells
(Fig. 7 C). These findings confirm the efficient presentation
of Ac2SGL during infection and highlight the bactericidal
potential of Ac2SGL-specific T cells.
Recognition of Ac2SGL by Lymphocytes from Tuberculosis Pa-
tients. To provide direct evidence for the activation of
Ac2SGL-specific T cells during tuberculosis we measured
IFN-  release by freshly isolated lymphocytes derived from
human donors. We recruited a large cohort of healthy do-
nors that were scored PPD  (n   54) or PPD  (n   51) ac-
cording to tuberculin skin testing. Ac2SGL selectively in-
duced IFN-  release in PPD  donors with a median of 312
pg/ml (Fig. 8 A). Only a minority of healthy PPD  donors
(n   4) responded to Ac2SGL. Most importantly, Ac2SGL
also stimulated T lymphocytes from patients with active
pulmonary tuberculosis (n   31). The levels of IFN-  se-
cretion were independent of susceptibility to disease, but
strictly dependent on previous contact with mycobacteria,
suggesting participation of sulfoglycolipid-reactive cells in
immune responses during infection with M. tuberculosis.
To confirm that these responses were dependent on
CD1-restricted T cells, representative experiments were
performed in the presence of CD1-blocking antibodies.
IFN-  release was largely dependent on CD1b (70%) and
CD1c (35%), but independent of CD1a, MHC class I, and
MHC class II (Fig. 8 B).
Discussion
Published studies indicate that mycobacterial lipid anti-
gens may stimulate CD1-restricted T cells. However, the
Figure 7. Ac2SGL-specific T cells
recognize and kill M. tuberculosis
H37Rv-infected cells. CD1  APCs
were pulsed with Ac2SGL or infected
with virulent M. tuberculosis and used
to stimulate the Z4B27 (A) or the
Z4A26 (B) T cell clones. Released
IFN-  was detected by ELISA. The
results are representative of four in-
dependent experiments. Bars indicate
SD. (C) Ac2SGL-specific T cells kill
intracellular  M. tuberculosis. CD1 
APCs were infected with virulent M. tuberculosis. Z4B27 T cells were added at different ratios as indicated. After 72 h of incubation, living intracellular
bacteria were counted as described in Materials and Methods. Average CFU   SEM calculated from four dilutions, each performed in duplicate are
shown. Similar results were obtained in two additional experiments.
Figure 8. Response of PBMCs to Ac2SGL ex vivo and inhibition with
anti-CD1 and anti-MHC mAbs. (A) PBMCs from healthy donors (PPD 
or PPD ) and from patients with pulmonary tuberculosis were cultured
in the presence of autologous CD1   APCs overnight pulsed with
Ac2SGL. Supernatants were harvested and IFN-  content was measured
by ELISA. Each dot presents an individual donor and the dashed line
depicts the detection threshold of 15 pg/ml of this assay. Unstimulated
samples served as controls and IFN-  was regularly below the level of
detection. (B) This graph summarizes the results   SEM from three
PPD  healthy donors using fraction 7 (10  g/ml) as antigen. IFN-  pro-
duction in the individual experiments was 473, 357, and 349 pg/ml.Gilleron et al. 657
pool of studied mycobacterial antigenic lipids is small com-
pared with the diversity of the lipid components of the M.
tuberculosis envelope. So far, only three classes of molecules
were shown to stimulate CD1b-restricted T cells: free my-
colic acids (13), mycoloyl glycolipids such as glucose mono-
mycolate (17), and phosphoglycolipids represented by li-
poarabinomannan (19), lipomannan (19), and PIM (20).
These molecules are commonly present in the envelope of
both virulent and nonvirulent mycobacteria. Their immu-
nogenicity during infection with virulent or avirulent
strains has not been compared.
In these studies we have characterized the structure of a
novel mycobacterial glycolipid, a diacylated sulfoglycolipid
(Ac2SGL), presented by CD1b on the cell surface of M. tu-
berculosis–infected APCs. This antigen stimulates bacteri-
cidal CD8  T cells and evokes strong responses in healthy
PPD  donors and tuberculosis patients.
Although M. tuberculosis sulfur-containing lipids have been
known for a long time, the purification of Ac2SGL and the
structural determination and identification of its immuno-
stimulatory capacity are novel. SGL were first described in
virulent M. tuberculosis (38). Later studies allowed identifica-
tion and characterization of a family of SGL (acylated treha-
lose 2 -sulfate) that were detectable only in M. tuberculosis
and their amounts correlated with the relative virulence in
guinea pigs (39). They were all identified as multi-acylated
trehalose sulfates differing from each other in the number
and type of acyl appendages and in the position on trehalose
(40). Very recently, sulfated molecules have been detected in
M. tuberculosis using Fourier transform-ion cyclotron reso-
nance mass spectrometry (41). Among them, a molecule
with a mass ascribed to Ac2SGL was evidenced from mass
spectra analysis. In other investigations, a sulfated compound
with a mass of 1,278 was found to accumulate in a mycobac-
terial mutant (42). In both of these studies Ac2SGL was not
purified and its exact chemical structure was not determined.
In our studies Ac2SGL was purified, its immunological im-
portance was recognized, and its structure was identified as
2-palmitoyl or 2-stearoyl-3-hydroxyphthioceranoyl-2 -sul-
fate- -  -d-trehalose using MALDI-Tof-MS, MS/MS, and
2D NMR spectroscopy. The purification strategy developed
also allowed the isolation of the previously described tetra-
acylated (SL-1, SL-I , SL-II) and tri-acylated (SL-III) SGL
(Ac4SGL and Ac3SGL, respectively; 43). These compounds
were unable to stimulate the Ac2SGL-specific T cell clones,
thus implying that immunogenic diacylated SGL are not
generated inside the APC as a result of antigen processing.
Ac2SGL is presented by CD1b to the isolated T cell
clones. Likely, CD1b presents Ac2SGL because of its unique
antigen-binding capacities. Analysis of the CD1b crystal
structure has revealed three hydrophobic pockets, denoted
A , C , and F , tailored for alkyl binding (23). A fourth
pocket, which resembles a tunnel and therefore is called “T
channel,” connects the A  and F  pockets. It has been pro-
posed that this unique structure could allow accommoda-
tion of very long fatty acids such as the C60 meromycolate
chain (44). As the major Ac2SGL acyl form is composed of a
C40 hydroxyphthioceranoic fatty acid and a palmitate or
stearate, it is tempting to speculate that the linear alkyl chain
of 32 carbon atoms is inserted in the A  or F  pockets and
protrudes into the T channel. This type of binding would
require a partial unfolding of the CD1b molecule, which
occurs in late endosomes (20). This hypothesis is indirectly
supported by the observation that Ac2SGL is presented only
when it is internalized by APCs into an acidic intracellular
compartment and is in agreement with similar findings ob-
tained with other glycolipid antigens (20).
In addition to CD1b, CD1c may also present Ac2SGL, as
suggested by the findings that anti-CD1c mAbs blocked a
minor but still relevant percentage (35%) of the response to
Ac2SGL in healthy PPD  donors. CD1c was found to
present mycobacterial lipids assigned to polyisoprenoid
phosphoglycolipids (14). In this case, the aliphatic chain
corresponds to a C32, which is in agreement with the chain
length of the major hydrophthioceranoic acid homologous.
This result also suggests that CD1c is characterized by at
least two lipid-binding pockets, as already inferred by the
demonstration that it presents sulfatide to T cells (26).
Finally, CD1a does not appear to participate in the pre-
sentation of Ac2SGL. Most likely the structure of CD1a
does not allow binding of the long chain hydroxyphthio-
ceranoic fatty acid (25) and therefore does not form immu-
nogenic complexes with Ac2SGL.
Ac2SGL-specific T cells release proinflammatory cyto-
kines such as IFN-  and TNF- , which may contribute to
the antimicrobial inflammatory response during infection.
Furthermore, these T cells are characterized by expression
of granulysin (unpublished data) and efficient bactericidal
capacities, as previously reported for other CD1- or MHC
class I–restricted T cells recognizing microbial products
(34, 45). Both properties endow these T cells with poten-
tial protective functions in vivo.
Ac2SGL is also highly immunogenic when presented by
APCs infected with M. tuberculosis. The response to these
SGL as measured ex vivo in the PBMCs of tuberculosis pa-
tients and of PPD  donors was much higher than that of
PPD   subjects. This applies not only to the average
amounts of released IFN- , but also to the percentage of
responding donors.
In conclusion, the powerful response in infected donors,
together with the capacity to prime protective T cells,
identifies Ac2SGL as a novel glycolipid with strong immu-
nogenicity during infection with M. tuberculosis. Therefore,
this antigen is a new glycolipid candidate to be tested as a
potential antimycobacterial subunit vaccine.
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